Publications
Selected publications of the Laboratory
(PI as first/last author)
2025
Pilard C, Roncarati P, Ancion M, Luyckx M, Renard M, Reynders C, Lerho T, Poulain F, Bruyere D, Lebeau A, Hendrick E, Crake R, Peiffer R, Nokin MJ, Peulen O, Delvenne P, Hubert P, Herfs M. RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells. Journal for ImmunoTherapy of Cancer, 13(3):e010753 (IF: 10.6)
Reynders C, Bruyere D, Roncarati P, Geuzaine R, Koopmansch B, Gofflot S, Monnien F, Craciun L, Piazzon N, Hendrick E, Poulain F, Lerho T, Miceli S, Pilard C, Ancion M, Luyckx M, Renard M, Lambert F, Gheit T, Molimard C, Bibeau F, Larsimont D, Fasquelle F, de Leval L, Delvenne P, Kervarrec T, Hubert P, Peulen O, Herfs M. Human Papillomavirus Infection Is a Favorable Prognostic Factor for Patients With Stages I to IVA Esophageal Squamous Cell Carcinoma but not Adenocarcinoma. Modern Pathology, 38(12):100853. (IF: 5.5)
2023
Bruyere, D., Roncarati, P., Lebeau, A., Lerho, T., Poulain, F., Hendrick, E., Pilard, C., Reynders, C., Ancion, M., Luyckx, M., Renard, M., Jacob, Y., Twizere, J.-C., Peiffer, R., Peulen, O., Delvenne, P., Hubert, P., McBride, A., Gillet, N., Masson, M., & Herfs, M. (2023). Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair. Theranostics, 13 (3), 1130-1149. (IF: 12.4)
2022
Lebeau, A.* , Bruyère, D.* , Roncarati, P., Peixoto, P., Hervouet, E., Cobraiville, G., Taminiau, B., Masson, M., Gallego, C., Mazzucchelli, G., Smargiasso, N., Fleron, M., Baiwir, D., Hendrick, E., Pilard, C., Lerho, T., Reynders, C., Ancion, M., Greimers, R., Twizere, JC., Daube, G., Schlecht-Louf, G., Bachelerie, F., Combes, JD., Melin, P., Fillet, M., Delvenne, P., Hubert, P., & Herfs, M. (2022). HPV infection alters vaginal microbiome through down regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nature Communications, 13 (1), 1076. (IF: 16.6) * These authors have contributed equally to this work.
2021
Hubert, P., Roncarati, P., Demoulin, S., Pilard, C., Ancion, M., Reynders, C., Lerho, T., Bruyère, D., Lebeau, A., Radermecker, C., Meunier, M., Nokin, M.-J., Hendrick, E., Peulen, O., Delvenne, P., & Herfs, M. (2021). Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Journal for ImmunoTherapy of Cancer, 9 ((3)), 001966. (IF: 12.469)
Pilard, C.* , Ancion, M.* , Delvenne, P., Jerusalem, G., Hubert, P., & Herfs, M. (2021). Cancer immunotherapy: it’s time to better predict patients’ response. British Journal of Cancer, 125(7), 927-938. (IF: 9.075) * These authors have contributed equally to this work.
Bruyère, D., Monnien, F., Colpart, P., Roncarati, P., Vuitton, L., Hendrick, E., Lepinoy, A., Luquain, A., Pilard, C., Lerho, T., Molimard, C., Maingon, P., Arnould, L., Bone-Lepinoy, M.-C., Dusserre, L., Martin, L., Reynders, C., Ancion, M., Peiffert, D., Leroux, A., Hubert, P., Delhorme, JB., Ghnassia, JP., Woronoff, AS., Delvenne, P., Prétet, JL., Bosset, JF., Peulen, O., Mougin, C., Valmary-Degano, S., & Herfs, M. (2021). Treatment algorithm and prognostic factors for patients with stage I–III carcinoma of the anal canal: a 20-year multicenter study. Modern Pathology, 34, 116-130. (IF: 8.209)
2018
Herfs, M., Roncarati, P., Koopmansch B., Peulen, O., Bruyere, B., Lebeau, A., Hendrick, E., Hubert, P., Poncin, A., Penny, W., Piazzon, N., Monnien, F., Guenat, D., Mougin, C., Prétet, JL., Vuitton, L., Segers, K., Lambert, F., Bours, V., de Leval, L., Valmary-Degano, S., Quick, CM., Crum, CP., Delvenne, P. (2018) A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalized medicine. British Journal of Cancer, 118(10), 1302-1312 (IF: 5.416)
2017
Herfs, M., Longuespée, R., Quick, CM., Roncarati, P., Suarez-Carmona, M., Hubert, P., Lebeau, A., Bruyere, D., Mazzucchelli, G., Smargiasso, N., Baiwir, D., Lai, K., Dunn, A., Obregon, F., Yang, EJ., De Pauw, E., Crum, CP., & Delvenne, P. (2017). Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. Journal of Pathology, 241, 522-533 (IF: 6.253)
2015
Herfs, M., & Crum, C. (2015). Cervical cancer: Squamocolumnar junction ablation-tying up loose ends? Nature Reviews Clinical Oncology, 12(7), 378-380. (IF: 18.786)
Demoulin, S., Somja, J., duray, A., guenin, S., Roncarati, P., Delvenne, P., Herfs, M.* , & Hubert, P.* (2015). Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion. OncoImmunology, 4, e1008334 (IF: 7.644) * These authors have contributed equally to this work.
Mirkovic, J., Howitt, B., Roncarati, P., Demoulin, S., Suarez-Carmona, M., Hubert, P., Mckeon, F., Xian,W., Delvenne, P., Crum, C. P., & Herfs, M. (2015). Carcinogenic HPV infection in the cervical squamo-columnar junction. Journal of Pathology, 236, 265-271. (IF: 7.381)
Suarez-Carmona, M., Hubert, P., Delvenne, P., & Herfs, M. (2015). Defensins: «simple» antimicrobial peptides or broadspectrummolecules ? Cytokine & Growth Factor Reviews, 26, 361-370. (IF: 6.571)
Herfs, M., Somja, J., Howitt, B. E., Suarez-Carmona, M., Kustermans, G., Hubert, P., Doyen, J., Goffin, F., Kridelka, F., Crum, C. P., & Delvenne, P. (2015). Unique recurrence patterns of cervical intraepithelial neoplasia following excision of the squamo-columnar junction. International journal of cancer, 136, 1043-1052. (IF: 5.531)
Yang, E. J., Quick, C. M., Hanamornroongruang, S., Lai, K., Doyle, L., McKeon, F. D., Xian, W., Crum, C. P., & Herfs, M. (2015). Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk. Modern Pathology, 28, 994-1000. (IF: 5.485)
2014
Hubert, P.* , Herman, L.* , Roncarati, P., Maillard, C., Renoux, V., Demoulin, S., Erpicum, C., Foidart, J.-M., Boniver, J., Noël, A., Delvenne, P., & Herfs, M. (2014). Altered alpha-defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour-permissive microenvironment. Journal of Pathology, 234(4), 464-77. (IF: 7.429)
* These authors have contributed equally to this work.
2013
Herfs, M., Vargas, S. O., Yamamoto, Y., Howitt, B. E., Nucci, M. R., Hornick, J. L., McKeon, F.D., Xian, W., & Crum, C. P. (2013). A novel blueprint for "top down" differentiation defines the cervical squamocolumnar junction during development, reproductive life and neoplasia. Journal of Pathology, 229(3), 460-8. (IF: 7.330)
Herfs, M., Parra-Herran, C., Howitt, B. E., Laury, A. R., Nucci, M. R., Feldman, S., Jimenez, C. A., McKeon,F.D., Xian, W., & Crum, C. P. (2013). Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of lowgrade squamous intraepithelial lesions. American journal of surgical pathology, 37(9), 1311-8. (IF: 4.592)
2012
Herfs, M., Yamamoto, Y., Laury, A., Wang, X., Nucci, M. R., McLaughlin-Drubin, M. E., Munger, K., Feldman, S., McKeon, F. D., Xian, W., & Crum, C. P. (2012). A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. PNAS, 109(26), 10516-21. (IF: 9.737)
